Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zilebesiran - Alnylam Therapeutics/Roche

Next Previous
Drug Profile

Zilebesiran - Alnylam Therapeutics/Roche

Alternative Names: AGT siRNA - Alnylam Pharmaceuticals; ALN-AGT; ALN-AGT-01; ALN-AGT01-RVR; RG-6615

Latest Information Update: 12 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Developer Alnylam Pharmaceuticals; Charite - Universitatsmedizin Berlin; Chugai Pharmaceutical
  • Class Antihypertensives; Small interfering RNA
  • Mechanism of Action Angiotensinogen expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypertension
  • No development reported Preeclampsia

Most Recent Events

  • 12 May 2026 Roche plans to file regulatory application for Hypertension in or after 2029 (Roche pipeline, May 2026)
  • 28 Apr 2026 Alnylam Pharmaceuticals plans a phase II trial for Hypertension in the USA (SC) (NCT07553442)
  • 27 Apr 2026 Alnylam Pharmaceuticals initiates a phase II trial for Hypertension in the USA (SC) (NCT07553442)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top